NXS - Next Science

and a bit later on, (meandering down the DNH path), we see NXS has dropped from $3+ a few years ago to 70c in June.

Today, a bit of a lift, from 80c to $1.05 based on a strong Quarterly?

• Product sales Q2 2022 +99% vs pcp, 70% on Q1 2022
• Signed multiple new distribution agreements in the Quarter to expand commercial reach and support for clinicians

Still a bit too much of the aspirational wording

A strategy to accelerate market awareness and adoption

Click to expand...

Dona Ferentes said:

Still a bit too much of the aspirational wording

Click to expand...

Yeah possibly so @Dona Ferentes i know nothing about the Company. A quick squiz at my initial "indicators" shows

Market Cap of around $206M Cap raise around March and currently have around $12M in the bank

Wide range bar on over average Volume, with a fair upper tail on todays +23% jump off recent lows

(Appropriate caution required at this stage would be my gut feel)

barney said:

(Appropriate caution required at this stage would be my gut feel)

Click to expand...

Managed a lift today on an early update... (still 'investing in sales and marketing' though)



In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above US$5.6m. This compares with reported product sales of US$4.4m in 1QFY23.

As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (US$5.2m) and 2HFY22 (US$6.1m). This is due to the increased investment in sales and marketing that will continue during the establishment phase of our direct sales model for key products.

As noted in the Chair’s AGM address on 26 May 2023, monthly sales in the Wound Care DME business surpassed $1m in April. Operating momentum has continued through the current quarter with ongoing evidence of sales traction in the commercial wound care market.

Glimmer of an uptick, in price if not volume, and along comes a TH

Capital raising by way of a placement and a share purchase plan

Click to expand...

quarterly and investor update out, and down she goes ⬇


.
5 year chart looks even worse

NH

down 15 percent today ..... 10c



.....a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees.

Mr Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr Morello and several former employees for breach of post-employment restraints.

Mr Morello’s complaint makes several claims including that Next Science’s XBIOTM technology has not been approved by the FDA as a biofilm eradication process and that the Company did
not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures.

The Company confirms that the products it sells are safe, effective, approved by the FDA and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged.

Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non-Compete Action against Mr Morello and several former employees for the breach of post-employment restraints.